Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ScinoPharm Taiwan Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

29 Oct 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ScinoPharm Taiwan Ltd (1789-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

01 Nov 2016 Thomson Reuters Stock Report 11 $25.00

Scinopharm Taiwan Limited: Downgraded to Average

31 Oct 2016 Sadif Analytics Prime 3 $10.00

Wright Investors Service Comprehensive Report for Scinopharm Taiwan Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

22 Oct 2016 Wright Reports 68 $75.00

ScinoPharm Taiwan, Ltd. (1789) - Financial and Strategic SWOT Analysis Review

ScinoPharm Taiwan, Ltd. (1789) - Financial and Strategic SWOT Analysis Review Summary ScinoPharm Taiwan, Ltd. (ScinoPharm) pr...

07 Oct 2016 GlobalData 52 $300.00

Should Investors Steer Clear of the Scinopharm Taiwan Limited?

24 Aug 2016 Sadif Analytics Prime 12 $25.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary Scinopharm Taiwan Limited (ScinoPharm) is a pharmaceutic...

19 Aug 2016 GlobalData 43 $300.00

ScinoPharm Taiwan (1789 TT): Good Margin yet Lacking Sales Momentum

We forecast ScinoPharm’s FY16 sales at NT$4.26bn, +8% YoY, with growth momentum mainly coming from generic drugs and the pla...

10 Aug 2016 MasterLink Securities Corporation 7 $69.00

神隆(1789.TT) 垂直整合成效非一蹴可及,評價不低,維持中立建議

垂直整合成效非一蹴可及,在評價仍不低下,維持中立建議:神隆近年積極透過其在原料藥開發上之豐沛經驗,持續有新產品上市,且為加速利潤跳增空間,公司在策略上也透過合作模式往下游製劑進行開發,惟此部分就公司Pipeline規劃,預見較明顯之獲利貢獻須待201...

08 Aug 2016 SinoPac Sec Inv Service 4 $23.00

神隆 (1789):毛利率表現佳,然營運缺乏動能

神隆2016年營收為42.6億元,YOY +8%,成長主要來自學名藥與常熟廠;毛利率部分,預估增加2.5%至44.9%,因10-DAB已經回到漲價前的水準,且10-DAB主要來自歐洲紅豆杉,歐元貶值對毛利率亦有助益,預估2016 EPS1.07元;元...

08 Aug 2016 MasterLink Securities Corporation 5 $35.00